Page ContentDate closed: 6/23/2015 Value: US$72.5 millionOn June 23, 2015, Cynapsus Therapeutics Inc. (Cynapsus) completed its underwritten public offering in the United States of common shares at US$14.00 per share, for total gross proceeds of approximately US$72.5 million. The offering was the first ever southbound-only underwritten equity offering under the Multijurisdictional Disclosure System and the issuer's initial public offering in the United States. On closing of the offering, Cynapsus' common shares commenced trading on the Nasdaq Global Market and are now dual listed on both NASDAQ and the Toronto Stock Exchange. Cynapsus, headquartered in Toronto, Ontario, is a pharmaceutical company focused on the treatment of OFF episodes in Parkinson's disease. BLG represented Cynapsus in Canada with a team led by Jeffrey S. Graham (Life Sciences) that included Jason Saltzman, Andrew Powers, Andrew Bunston (Securities, Corporate) and Daniel Lang (Tax).